HOME / Featured News / WORLD NEWS
FDA Supplement Guidance Not Strict Enough, MD Says
Rate This Article:
0

Medpagetoday.com REPORTS HERE that "an FDA proposal to require dietary supplement manufacturers to submit data proving their product is safe doesn't go far enough, according to a physician writing in the New England Journal of Medicine."

"More than 100 million Americans spend more than $28 billion on vitamins, minerals, herbal ingredients, amino acids and other natural products in the form of dietary supplements each year, "assuming they are both safe and effective," … But they have no assurance that the products are safe because FDA regulation of supplements is too weak …."

"By law, ingredients that were used and sold in supplements prior to 1994 can be marketed without any proof that they are safe or effective. But under a law called the Dietary Supplement Health and Education Act (DSHEA), manufacturers of any ingredient introduced after 1994 must provide the FDA with evidence supporting 'a reasonable expectation of safety.'"

"Since DSHEA became law more than 15 years ago, the number of supplements on the market has gone from 4,000 to more than 55,000. Since 1994, the FDA has received proper notification for 170 new supplement ingredients, "undoubtedly a small fraction of the ingredients for which safety data should have been submitted."

"The FDA has mounted a new effort to discourage the sale and use of nutritional supplements that contain ingredients that are regulated as drugs. Last year, the agency issued draft guidance meant to inform supplement manufacturers about what information they must submit to the FDA, including spelling out when an ingredient is considered old and when it's considered new. (A synthetically produced replica of a botanical product, for instance, would be considered new)."

"In addition, the FDA is proposing that the guidance call for in vitro, animal, and long-term tolerability testing for supplements that would be marketed at higher doses than those historically ingested."

"The dietary supplement industry largely opposes the draft regulation."


 
Post A Comment
* Indicates Required Field
Comment Title:
* Comments:
Nickname:
* Validation:
Most Recent Comments
 
 
FeaturedNews
Clinical Trial Data Should Be Open for Review
Published 04/30/2012 - 3:14 p.m.  CDT

Original clinical study reports, which contain far more detail than published randomized trials, should be made available to independent researchers seeking to verify efficacy and safety claims.

In support of this argument, the history of the influenza antiviral oseltamivir (Tamiflu), which was approved by the FDA in 1999, was cited. The widespread belief in oseltamivir's efficacy, was based on a meta-analysis of 10 trials conducted by the manufacturer prior to licensure.  But the authors pointed out that the FDA, which was aware of these clinical trials, concluded that oseltamivir had not been shown to reduce complications and required a statement on the drug's label to that effect.  Moreover, oseltamivir was not given an FDA indication for prevention of spread of influenza.

To this, [authors] commented, "If FDA is right, the drug's effectiveness may be no better than aspirin or acetaminophen.'"
...Read More
HR 329 in need of Co Sponsors
Published 04/30/2012 - 11:11 a.m.  CDT

Representative Bob Filner recently introduced the Chiropractic Care to All Veterans Act (H.R. 329). The bill would require the Veterans Administration (VA) to have a chiropractic physician on staff at all major VA medical facilities by 2014. You too can help ensure chiropractic care is available to those who have placed their lives in service to our country. H.R. 329 is in need of cosponsors to assist its likelihood of passage.

CLICK HERE to urge your legislators to cosponsor the bill.
...Read More
Court Sides with Generic-Drug Makers
Published 04/25/2012 - 6:33 a.m.  CDT

In a unanimous decision, the Supreme Court ruled that generic drugmaker Caraco Pharmaceutical Laboratories can sue Novo Nordisk for what Caraco says are exaggerated descriptions of the scope of patents Novo Nordisk holds on a diabetes drug.

A group of Democratic senators has introduced a bill that would allow people to sue generic drugmakers over failing to update their drug labels to include all known risks. The bill is meant to counter last year's Supreme Court decision in a generic drug dispute.
...Read More
Reader Login
Username:
Password:
 Save Login?
Free Sign-up
Forgot Password?
Reader Control Panel

The TCA Web sites will be under going change in the next few weeks.  Please bear with us while we complete some improvements.

Original clinical study reports, which contain far more detail than published randomized trials, should be made available to independent researchers seeking to verify efficacy and safety claims.

In support of this argument, the history of the influenza antiviral oseltamivir (Tamiflu), which was approved by the FDA in 1999, was cited. The widespread belief in oseltamivir's efficacy, was based on a meta-analysis of 10 trials conducted by the manufacturer prior to licensure.  But the authors pointed out that the FDA, which was aware of these clinical trials, concluded that oseltamivir had not been shown to reduce complications and required a statement on the drug's label to that effect.  Moreover, oseltamivir was not given an FDA indication for prevention of spread of influenza.

To this, [authors] commented, "If FDA is right, the drug's effectiveness may be no better than aspirin or acetaminophen.'"

The Kilgore College Small Business Development Center (SBDC) will sponsor an educational seminar for medical office staff, including office managers and billing staff, entitled Basic Workers’ Compensation for Medical Office Staff on Wednesday, May 2, 2012.

Representative Bob Filner recently introduced the Chiropractic Care to All Veterans Act (H.R. 329). The bill would require the Veterans Administration (VA) to have a chiropractic physician on staff at all major VA medical facilities by 2014. You too can help ensure chiropractic care is available to those who have placed their lives in service to our country. H.R. 329 is in need of cosponsors to assist its likelihood of passage.

CLICK HERE to urge your legislators to cosponsor the bill.

An $8 billion Medicare demonstration program is poorly designed and should be cancelled, the nonpartisan Government Accountability Office (GAO) said. The program is designed to reward the highest-quality Medicare Advantage plans, but instead pays out most of its award money to mediocre plans, according to a report.


Ethiopia and Kenya Trips.  Have you ever wanted to provide chiropractic care in another country and give back to those in need?

Dr. Teresa Jones has been volunteering on mission trips to Africa for 4 years and is reaching out to the District 5 for help this year. There are two chances to participate, both in July 2012 and if you are interested please RSVP to frontdesk@wholehealth-care.com to let her know you area interested!


The Patient-Centered Outcomes Research Initiative (PCORI), established by the 2010 Patient Protection and Affordable Care Act, has set five priorities as the group's research agenda for the coming years, with the overall goal of advancing clinical effectiveness research. …. the priorities [are] as follows...

Girls who face multiple social stressors at home as toddlers are more likely to be obese by age 5, researchers found.

Nonpharmacologic pain management appears to be safe for mother and baby, although there is limited published evidence to explain its efficacy, according to a Cochrane Review.

There is more data to support the ef?cacy of pharmacologic pain management, such as epidurals and opioids, but these methods lead to more adverse effects.  This reports reports upon some of these
Regulators on both sides of the Atlantic were slow to inform patients and their doctors about problems with metal-on-metal hip implants and relied on industry officials and consultants in crafting their responses.

Complications included high failure rates and possible systemic effects from elevated metal ion levels in the blood.  An advisory has been issued to surgeons, telling them that patients who have received metal-on-metal implants should have annual checkups for life. The evaluations should include testing for metal ions in the blood as well as for clinical symptoms of device failure.